OXBOF: AI 评分 49/100 — AI 分析 (4月 2026)

Oxford BioDynamics Plc is a biotechnology company focused on discovering and developing epigenetic biomarkers. Their proprietary EpiSwitch platform is used for disease prediction, diagnosis, and treatment across various medical fields.

Key Facts: AI Score: 49/100 Sector: Healthcare

公司概况

概要：

Oxford BioDynamics Plc leverages its EpiSwitch platform to discover and develop epigenetic biomarkers for disease prediction and treatment. The company operates in the biotechnology sector, offering diagnostic and prognostic tools like EpiSwitch CiRT and CST, primarily targeting the pharmaceutical and biotechnology industries internationally.

OXBOF是做什么的？

Oxford BioDynamics Plc, incorporated in 2007 and headquartered in Oxford, UK, is a biotechnology company specializing in the discovery and development of biomarkers. The company's core technology is EpiSwitch, a proprietary platform that identifies and validates chromosome conformation signatures for use as epigenetic biomarkers. These biomarkers are applied in medical testing kits, disease prediction, diagnosis, and treatment monitoring. The company's key products include EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a prognostic test designed to predict a patient's response to checkpoint inhibitor immunotherapy. Another product, EpiSwitch CST (Covid Severity Test), is a blood test aimed at predicting the severity of COVID-19 in adults. Additionally, Oxford BioDynamics offers the EpiSwitch Explorer Array Kit, which facilitates high-resolution 3D genome profiling and biomarker discovery. Oxford BioDynamics primarily serves the pharmaceutical and biotechnology industries, focusing on developing tools that can improve drug development, clinical trials, and patient outcomes. The company operates both in the United States and internationally, seeking partnerships and collaborations to expand the reach of its EpiSwitch technology and biomarker portfolio.

OXBOF的投资论点是什么？

Oxford BioDynamics presents a high-risk, high-reward investment profile within the biotechnology sector. The company's proprietary EpiSwitch platform offers a unique approach to biomarker discovery with potential applications across various diseases. A key value driver is the successful commercialization of EpiSwitch CiRT, which could generate revenue through predicting patient response to immunotherapy. The company's ability to secure partnerships with pharmaceutical companies for biomarker discovery and drug development is also crucial. However, the company's negative profit and gross margins (-1018.5% and -561.6%, respectively) highlight financial challenges. Upcoming data releases from clinical studies using EpiSwitch and regulatory approvals for its diagnostic tests are potential catalysts. Investors should closely monitor the company's cash burn rate and ability to secure additional funding to sustain operations.

OXBOF在哪个行业运营？

Oxford BioDynamics operates within the competitive biotechnology industry, which is characterized by rapid innovation and high regulatory hurdles. The market for biomarker discovery and diagnostics is growing, driven by the increasing demand for personalized medicine and targeted therapies. Companies like Oxford BioDynamics face competition from established players in genomics and proteomics, as well as other emerging biotechnology firms. The company's success depends on its ability to differentiate its EpiSwitch platform, secure regulatory approvals, and establish partnerships with pharmaceutical companies.

Biotechnology

Healthcare

OXBOF有哪些增长机遇？

Expansion of EpiSwitch CiRT into new cancer types: The EpiSwitch CiRT test is currently focused on predicting response to checkpoint inhibitors in specific cancers. Expanding its application to other cancer types represents a significant growth opportunity. The global oncology market is projected to reach $286.6 billion by 2028, providing a large addressable market for CiRT and future diagnostic tests. Timeline: Ongoing clinical trials and validation studies are expected to support expansion over the next 2-3 years.
Development of new diagnostic tests for autoimmune diseases: Autoimmune diseases represent a significant unmet medical need, and the EpiSwitch platform could be used to develop novel diagnostic tests. The global autoimmune disease diagnostics market is projected to reach $16.1 billion by 2027. Oxford BioDynamics could leverage its technology to capture a share of this market. Timeline: Research and development efforts are likely to span 3-5 years before a commercially viable product is available.
Partnerships with pharmaceutical companies for drug development: Oxford BioDynamics can partner with pharmaceutical companies to use the EpiSwitch platform to identify biomarkers for drug development. This could generate revenue through licensing agreements, milestone payments, and royalties on sales of drugs developed using the company's biomarkers. The pharmaceutical industry spends billions of dollars annually on drug discovery and development, creating a substantial market for biomarker-based services. Timeline: Partnership agreements could be established within the next 1-2 years, with revenue generation dependent on the success of drug development programs.
Geographic expansion into Asia and Europe: Oxford BioDynamics currently focuses on the United States and international markets. Expanding into Asia and Europe represents a growth opportunity, particularly in countries with advanced healthcare systems and a growing demand for personalized medicine. The Asia-Pacific diagnostics market is projected to be the fastest-growing region globally. Timeline: Expansion efforts could begin within the next 2 years, with a focus on establishing partnerships and distribution networks.
Application of EpiSwitch technology to personalized medicine: The EpiSwitch platform can be used to develop personalized medicine approaches, tailoring treatment decisions to individual patients based on their epigenetic profiles. The personalized medicine market is growing rapidly, driven by advances in genomics and proteomics. Oxford BioDynamics can position itself as a leader in epigenetic-based personalized medicine. Timeline: Development of personalized medicine applications is a long-term effort, likely to span 5-10 years.

EpiSwitch Platform: Proprietary technology for epigenetic biomarker discovery.
EpiSwitch CiRT: Validated prognostic test for predicting response to checkpoint inhibitor immunotherapy.
EpiSwitch CST: Advanced blood test for predicting COVID-19 severity in adults.
Market Cap: $0.00B indicates the company is a micro-cap stock.
Negative Profit Margin: -1018.5% signals significant losses and operational inefficiencies.

OXBOF提供哪些产品和服务？

Discovers epigenetic biomarkers using its proprietary EpiSwitch platform.
Develops diagnostic and prognostic tests for various diseases.
Offers the EpiSwitch CiRT test to predict response to cancer immunotherapy.
Provides the EpiSwitch CST test for predicting COVID-19 severity.
Offers the EpiSwitch Explorer Array Kit for high-resolution 3D genome profiling.
Partners with pharmaceutical companies for biomarker discovery and drug development.

OXBOF如何赚钱？

Generates revenue through the sale of diagnostic and prognostic tests.
Partners with pharmaceutical companies for biomarker discovery and drug development, earning licensing fees, milestone payments, and royalties.
Offers services for high-resolution 3D genome profiling and biomarker discovery using the EpiSwitch Explorer Array Kit.

Pharmaceutical companies seeking biomarkers for drug development.
Biotechnology companies developing diagnostic and therapeutic products.
Hospitals and clinics using diagnostic tests for patient care.
Research institutions conducting studies on epigenetics and disease.

Proprietary EpiSwitch platform: Provides a unique technology for epigenetic biomarker discovery.
Validated diagnostic tests: EpiSwitch CiRT and CST have demonstrated clinical utility.
Expertise in epigenetics: Oxford BioDynamics has a team of scientists with expertise in epigenetics and biomarker discovery.
Partnerships with pharmaceutical companies: Provides access to resources and expertise for drug development.

什么因素可能推动OXBOF股价上涨？

Upcoming: Data releases from clinical studies using EpiSwitch for biomarker discovery.
Upcoming: Potential regulatory approvals for EpiSwitch CiRT and other diagnostic tests.
Ongoing: Expansion of partnerships with pharmaceutical companies for drug development.
Ongoing: Increasing adoption of EpiSwitch technology in personalized medicine.
Ongoing: Development of new diagnostic tests for autoimmune diseases.

OXBOF的主要风险是什么？

Ongoing: Negative profit and gross margins raise concerns about financial sustainability.
Potential: Competition from established players in genomics and proteomics.
Potential: Regulatory hurdles for diagnostic tests.
Potential: Failure to secure additional funding.
Ongoing: Limited liquidity due to OTC market listing.

OXBOF的核心优势是什么？

Proprietary EpiSwitch platform for epigenetic biomarker discovery.
Validated diagnostic tests like EpiSwitch CiRT and CST.
Expertise in epigenetics and biomarker development.
Potential for partnerships with pharmaceutical companies.

OXBOF的劣势是什么？

Negative profit and gross margins.
Limited commercialization of products.
Dependence on external funding.
OTC market listing indicates higher risk.

OXBOF有哪些机遇？

Expansion of EpiSwitch CiRT into new cancer types.
Development of new diagnostic tests for autoimmune diseases.
Partnerships with pharmaceutical companies for drug development.
Geographic expansion into Asia and Europe.

OXBOF面临哪些威胁？

Competition from established players in genomics and proteomics.
Regulatory hurdles for diagnostic tests.
Failure to secure additional funding.
Uncertainty in the biotechnology industry.

OXBOF的竞争对手是谁？

AnPac Bio-Medical Science Co Ltd — Focuses on early cancer screening and detection technologies. — (ANPCY)
Chemomab Therapeutics Ltd — Develops novel therapeutics for inflammatory and fibrotic diseases. — (CHMMF)
Dovre Group Oyj — Provides project management and consulting services. — (DVHGF)
Hookipa Pharma Inc — Develops immunotherapies for infectious diseases and cancer. — (HOOK)
Immunic Inc — Develops oral therapies for chronic inflammatory and autoimmune diseases. — (IMUC)

Key Metrics

MoonshotScore: 49/100

Company Profile

CEO: Iain Gladstone Ross
Headquarters: Oxford, GB
Employees: 51
Founded: 2020

AI Insight

AI analysis pending for OXBOF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Oxford BioDynamics Plc do?

Oxford BioDynamics Plc is a biotechnology company that focuses on discovering and developing epigenetic biomarkers using its proprietary EpiSwitch platform. This platform analyzes chromosome conformation signatures to identify biomarkers for disease prediction, diagnosis, and treatment monitoring. The company's products include diagnostic tests like EpiSwitch CiRT for predicting response to cancer immunotherapy and EpiSwitch CST for predicting COVID-19 severity. Oxford BioDynamics also partners with pharmaceutical companies to develop biomarkers for drug development, positioning itself as a key player in personalized medicine.

What do analysts say about OXBOF stock?

As of 2026-03-17, a comprehensive analyst consensus on OXBOF is not available in the provided data. Given its micro-cap status and OTC listing, analyst coverage may be limited. Key valuation metrics such as P/E ratio (-0.25) and negative profit margins (-1018.5%) suggest the company is currently unprofitable. Growth considerations revolve around the successful commercialization of its EpiSwitch platform, regulatory approvals for its diagnostic tests, and partnerships with pharmaceutical companies. Investors should conduct their own due diligence and consider the risks associated with investing in a micro-cap OTC stock.

What are the main risks for OXBOF?

The main risks for Oxford BioDynamics Plc include its negative profit and gross margins, which raise concerns about its financial sustainability. Competition from established players in the biotechnology industry, particularly in genomics and proteomics, poses a threat. Regulatory hurdles for diagnostic tests and the potential failure to secure additional funding are also significant risks. Additionally, the company's OTC market listing indicates higher risk due to limited liquidity and disclosure requirements. Investors should carefully consider these risks before investing in OXBOF.